Curis InitiatesRoche-Sponsored Phase 1b/2 Study of Erivedge in Relapsed/Refractory AML and High Risk MDS

Curis (NASDAQ: CRIS ), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that Roche (OTC: RHHBY ) initiated a Phase 1b/2 study of Erivedge® (vismodegib) in patients with relapsed/ refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS). Roche